Skip to main content
Premium Trial:

Request an Annual Quote

Axiom Will Adapt Screening Technology to Bioinformatics Database


SAN DIEGO--Axiom Biotech nolo gies has announced plans to use its proprietary High-Throughput Pharmacological Screening (HT-PS) system technology as a platform to develop a new bioinformatics resource, the PharmaProfile database. The database would correlate chemical structures with potential biological activity, potency, and selectivity, enabling drug research ers to rapidly evaluate drug candidate feasibility and accelerate the enhancement of lead potency and specificity by directing compound optimization strategies, according to the company.

The first HT-PS system is scheduled to be delivered and licensed to Cadus Pharmaceutical Corp., Tarrytown, N.Y., after Cadus invested $2 million in Axiom's preferred stock. The investment represents approximately a 26 percent stake in Axiom. If Cadus receives and accepts the system within a contractually specified time, it will buy another $2 million in preferred stock, raising its share of Axiom to 38 percent.

Cadus is engaged in the discovery of novel small-molecule therapeutics, with a particular emphasis on the development of proprietary technologies that exploit the similarities between yeast and human genomes. Axiom's primary focus is accelerating the drug development process through high-throughput pharmacological screening and more efficient lead compound optimization. The proprietary HT-PS system measures immediate physiological responses of human cells, automating the process of assessing the pharmacological properties of potential therapeutic compounds, according to Axiom.

In conjunction with Cadus's investment in Axiom, Jeremy Levin and Philip Sussman, respectively Cadus's CEO and vice-president of corporate development, were appointed to Axiom's board of directors, where they join Pandi Veerapandian and Ilya Okun, Axiom's president and chief scientific officer, and vice-president of pharmacology.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.